| Name | Fetuin A |
|---|---|
| Synonyms | A2HS; AHS; AHSG; AHSG Fetuin A; Alpha 2 HS glycoprotein; Alpha 2 HS glycoprotein precursor; Alpha 2 Z globulin; Alpha2 Heremans Schmid glycoprotein… |
| Name | phosphorus |
|---|---|
| CAS | phosphorus |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 20091488 | Cottone S, Palermo A, Arsena R, Riccobene R, Guarneri M, Mule G, Tornese F, Altieri C, Vaccaro F, Previti A, Cerasola G: Relationship of fetuin-A with glomerular filtration rate and endothelial dysfunction in moderate-severe chronic kidney disease. J Nephrol. 2010 Jan-Feb;23(1):62-9. Multiple regression analysis showed that fetuin-A was independently associated with estimated glomerular filtration rate (beta=0.386; p <0.001), IL-6 (beta=-0.393; p=0.001) and ET-1 (beta=-0.219; p=0.02), in a multivariate model including also sex, parathyroid hormone and the x phosphorus product. |
38(0,1,1,8) | Details |
| 19345526 | Torres PA: [Origin of the mediacalcosis in kidney failure] . J Mal Vasc. 2009 May;34(3):204-10. Epub 2009 Apr 3. It is now possible to identify factors clearly favoring the formation of VC: TNF-alpha (which stimulates cell necrosis/apoptosis), CRP, oxidized lipids, AGEs, leptin, inorganic high -phosphorus product (CaxPO (4)), 1,25-OH (2) D (3) and (3), PTHrP (via an intracrine pathway), cyclic AMP, TGF-beta, bone morphogenic protein 2 (BMP2) and factors protective against the formation of VC: HDL, inorganic albumin, ahsg/fetuin A, osteopontin (OPN), osteoprotegerin (OPG), osteonectin (ON), bone morphogenic protein 7 (BMP7), klotho, PTHrP (via a paracrine pathway), matrix gla protein (MGP), PTH (via Msx2) and |
31(0,1,1,1) | Details |
| 20124547 | Avila M, Prado C, Ventura MD, Mora C, Briones D, Valdez H, Hurtado ME, Lindholm B, Qureshi A, Castillo-Henkel C, Paniagua R: receptor gene, biochemical bone markers and bone mineral density in Mexican women on dialysis. Nephrol Dial Transplant. 2010 Feb 2. METHODS: In a cross-sectional study, 197 women (42 +/- 10 years; 25% with diabetes mellitus (DM); body mass index (BMI) 25.26 +/- 4.77 kg/ treated by PD (72%) or HD (28%) underwent measurements of BMD (measured at the calcaneus by quantitative ultrasound; expressed as T- and Z-scores) and plasma total (tCa), intact parathyroid hormone 1-84 (iPTH), phosphorus, albumin, osteoprotegerin (OPG), fetuin-A, intact osteocalcin-49 and N-MID fragment 1-43 aa (N-MID osteocalcin) N-terminal propeptide of type 1 procollagen (PINP) and C-terminal telopeptide-beta aspartic acid (BCL). |
6(0,0,1,1) | Details |
| 19329792 | Koleganova N, Piecha G, Ritz E, Schirmacher P, Muller A, Meyer HP, Gross ML: Arterial calcification in patients with chronic kidney disease. . Nephrol Dial Transplant. 2009 Aug;24(8):2488-96. Epub 2009 Mar 27. In contrast, staining for transglutaminase-2 and Fetuin A was significantly reduced in CKD. and phosphorus content in the aorta was quantitated using x-ray analysis. |
1(0,0,0,1) | Details |
| 19946324 | Brandenburg VM, Jahnen-Dechent W, Ketteler M: Sevelamer and the bone-vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation. Kidney Int Suppl. 2009 Dec;(114):S26-33. These include effects on bone turnover and the link between abnormal vascular processes and bone metabolism (the so-called 'bone-vascular axis'), as well as lipid metabolism, and systemic inflammatory mediators such as fetuin-A. Mainstays of hyperphosphatemia treatment are reduction of dietary phosphorus, use of binders, and optimized phosphorus removal via dialysis. |
1(0,0,0,1) | Details |